(NASDAQ:AMLX) shares are up 20% again in pre-market trading on news of the FDA extending the review timeline of it’s new drug application.  Shares are trading at $11.94 a share on more than 7,000 trades.

New PDUFA goal date scheduled for September 29, 2022 to allow time to review additional data

RelatedNews

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist